PROSTATE CANCER: Clinical data suggest that ATM loss does not confer sensitivity to PARP inhibition

Kevin Sovet

June 10, 2020

SCIENTIFIC

PROSTATE CANCER

Clinical data suggest that ATM loss does not confer sensitivity to PARP inhibition; however, preclinical studies suggest ATM loss enhances sensitivity to ATR inhibition; ATR inhibitors are in clinical development.

 

ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

DOI: 10.1158/0008-5472.CAN-19-3126

Abstract

Alterations in DNA damage response (DDR) genes are common in advanced prostate tumors and are associated with unique genomic and clinical features. ATM is a DDR kinase that has a central role in coordinating DNA repair and cell-cycle response following DNA damage, and ATM alterations are present in approximately 5% of advanced prostate tumors. Recently, inhibitors of PARP have demonstrated activity in advanced prostate tumors harboring DDR gene alterations, particularly in tumors with BRCA1/2 alterations. However, the role of alterations in DDR genes beyond BRCA1/2 in mediating PARP inhibitor sensitivity is poorly understood. To define the role of ATM loss in prostate tumor DDR function and sensitivity to DDR-directed agents, we created a series of ATM-deficient preclinical prostate cancer models and tested the impact of ATM loss on DNA repair function and therapeutic sensitivities. ATM loss altered DDR signaling, but did not directly impact homologous recombination function. Furthermore, ATM loss did not significantly impact sensitivity to PARP inhibition but robustly sensitized to inhibitors of the related DDR kinase ATR. These results have important implications for planned and ongoing prostate cancer clinical trials and suggest that patients with tumor ATM alterations may be more likely to benefit from ATR inhibitor than PARP inhibitor therapy.

more info: https://clincancerres.aacrjournals.org/content/26/11/2487 and https://cancerres.aacrjournals.org/content/80/11/2094